Puma Biotechnology | PBYI - Sales Revenues


Puma Biotechnology reported $80.54M in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Amgen USD 10.1B 1.48B Jun/2026
Biogen USD 2.74B 490M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Daiichi Sankyo JPY 574.74B 12.26B Jun/2026
Exelixis USD 628.69M 17.89M Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Incyte USD 1.67B 400M Jun/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Moderna USD 100M 289M Jun/2026
Novartis USD 14.41B 1.3B Jun/2026
Pfizer USD 15.03B 530M Jun/2026
PTC Therapeutics USD 361M 88M Jun/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Takeda JPY 1.22T 130B Jun/2026
TG Therapeutics USD 240.34M 45.54M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026